* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Antiepilepsy Drugs: pharmacodynamics and
Survey
Document related concepts
Drug discovery wikipedia , lookup
Psychedelic therapy wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Adherence (medicine) wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Pharmacognosy wikipedia , lookup
Drug interaction wikipedia , lookup
Neuropharmacology wikipedia , lookup
Psychopharmacology wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Theralizumab wikipedia , lookup
Lamotrigine wikipedia , lookup
Transcript
Epilepsy Board Review Manual Statement of Editorial Purpose The Epilepsy Board Review Manual is a study guide for trainees and practicing physicians preparing for board examinations in epilepsy. Each manual reviews a topic essential to the current management of patients with epilepsy. PUBLISHING STAFF PRESIDENT, Group PUBLISHER Bruce M. White Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Contributor and Editor: Thomas R. Henry, MD Professor of Neurology, Director, Comprehensive Epilepsy Center, University of Minnesota Medical School, Minneapolis, MN Contributor: Jeannine M. Conway, PharmD Assistant Professor of Pharmacy, University of Minnesota College of Pharmacy, Minneapolis, MN Senior EDITOR Robert Litchkofski executive vice president Barbara T. White executive director of operations Jean M. Gaul Table of Contents Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 Principles of Drug Selection and Dosing. . . . . . . 1 Summary of Antiepileptic Drugs . . . . . . . . . . . . 12 Other Considerations. . . . . . . . . . . . . . . . . . . . . 17 NOTE FROM THE PUBLISHER: This publication has been developed with out involvement of or review by the Amer ican Board of Psychiatry and Neurology. Board Review Questions. . . . . . . . . . . . . . . . . . . 18 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Epilepsy Board Review Manual Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Jeannine M. Conway, PharmD, and Thomas R. Henry, MD Introduction Pharmacologic management of seizures in individual patients mainly involves drug selection based on the individual patient’s epilepsy syndrome and risks for toxicity with particular agents, followed by ongoing surveillance for antiseizure efficacy and adverse effects. These aspects of the interaction between particular drugs and individuals’ brains and other organ systems are considered the pharmacodynamics of antiepileptic drugs (AEDs), in distinction to the absorption, distribution, and elimination of drugs and drug-drug interactions, or pharmacokinetics, of AEDs. Drug selection by epilepsy syndrome may be informed by randomized prospective trials with explicit entry criteria that define a syndrome and report efficacy of an AED versus placebo with statistically rigorous analyses, and by expert consensus statements.1,2 In addition to warnings and toxicity information issued by the U.S. Food and Drug Administration (FDA), expert consensus statements also play a major role in avoidng and managing adverse effects of AEDs.3 Principles of drug selection and dosing Initial monotherapy A dilemma encountered by prescribers is determining which antiepileptic medication should be prescribed first. The majority of the data indicate that, particularly for focal seizures, medications are essentially equally efficacious, but some statistically significant differences can be found in tolerability and side effects.4–7 The great majority of industry-sponsored clinical trials are designed as placebo-controlled, add-on therapy, prospective trials in subjects whose seizures are not well controlled by their current medications. The inclusion criteria may vary slightly, but they most often include adults with a diagnosis of complex partial seizures. As a result, most AEDs are launched initially to market to be used as adjunctive therapy with an existing AED regimen (Table 1). It is therefore difficult to extrapolate the results of those studies to all patients seen in clinic, as many may not be refractory and may not be adults. Copyright2012,TurnerWhiteCommunications,Inc.,StraffordAvenue,Suite220,Wayne,PA19087-3391,www.turner-white.com. Allrightsreserved.Nopartof thispublication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior writtenpermissionof TurnerWhiteCommunications.Thepreparationanddistributionof thispublicationaresupportedbysponsorshipsubjecttowrittenagreementsthatstipulate and ensure the editorial independence of Turner White Communications. Turner White Communications retains full control over the design and production of all published materials, including selection of topics and preparation of editorial content. The authors are solely responsible for substantive content. Statements expressed reflect the views of the authors and not necessarily the opinions or policies of Turner White Communications. Turner White Communications accepts no responsibility for statements made by authors and will not be liable for any errors of omission or inaccuracies. Information contained within this publication should not be used as a substitute for clinical judgment. www.turner-white.comEpilepsy Volume 1, Part 6 1 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 1. Antiepileptic Drug FDA-Approved Indications Medication First generation Carbamazepine Ethosuximide Phenobarbital Phenytoin Valproic acid† Second generation Clobazam Felbamate Gabapentin Lamotrigine Levetiracetam Oxcarbazepine Pregabalin Rufinamide Tiagabine Topiramate Vigabatrin Zonisamide Third generation Ezogabine Lacosamide Perampanel FDA-Approved Indications POS, GTC seizures, mixed seizure patterns* Absence seizures* Not an FDA-approved medication Control of GTC seizures (grand mal) and CPS (psychomotor, temporal lobe) and prevention and treatment of seizures occurring during or following neurosurgery Monotherapy and adjunctive therapy in the treatment of adult patients and pediatric patients down to age 10 years with CPS that occur either in isolation or in association with other types of seizures; also indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures in adults and children aged ≥10 years, and adjunctively in adults and children aged ≥10 years with multiple seizure types that include absence seizures Adjunctive treatment of seizures associated with LGS in patients aged ≥2 years Monotherapy or adjunctive therapy in the treatment of POS, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with LGS in children Adjunctive therapy in the treatment of POS with and without secondary generalization in patients over age 12 years with epilepsy; also indicated as adjunctive therapy in the treatment of POS in pediatric patients aged 3–12 years Adjunctive therapy for the following seizure types in patients aged ≥2 years: POS, primary GTC seizures, generalized seizures of LGS; indicated for conversion to monotherapy in adults (age ≥16 years) with POS who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED Adjunctive therapy in the treatment of POS in adults and children aged ≥1 month with epilepsy and as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents aged ≥12 years with JME; also indicated as adjunctive therapy in the treatment of primary GTC seizures in adults and children aged ≥6 years with idiopathic generalized epilepsy Monotherapy or adjunctive therapy in the treatment of POS in adults and as monotherapy in the treatment of POS in children aged ≥4 years with epilepsy, and as adjunctive therapy in children aged ≥2 years with POS Adjunctive therapy for adult patients with POS Adjunctive treatment of seizures associated with LGS in children aged ≥4 years and adults Adjunctive therapy in adults and children aged ≥12 years in the treatment of POS Initial monotherapy in patients aged ≥2 years with POS or primary GTC seizures; safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials; also indicated as adjunctive therapy for adults and pediatric patients ages 2–16 years with POS or primary GTC seizures, and in patients aged ≥2 years with seizures associated with LGS Adjunctive therapy for adult patients with refractory CPS who have inadequately responded to several alternative treatments and for whom the potential benefits outweigh the risk of vision loss and monotherapy for pediatric patients with infantile spasms for whom the potential benefits outweigh the potential risk of vision loss Adjunctive therapy in the treatment of POS in adults with epilepsy Adjunctive treatment of POS in patients aged ≥18 years Adjunctive therapy in the treatment of POS in patients with epilepsy aged ≥17 years Adjunctive therapy for the treatment of POS with or without secondarily generalized seizures in patients with epilepsy aged ≥12 years AED = antiepileptic drug; CPS = complex partial seizures; GTC = generalized tonic-clonic; JME = juvenile myoclonic epilepsy; LGS = LennoxGastaut syndrome; POS = partial-onset seizures. *Age of patients not specified by label. †Age not specified in enteric-coated valproate label; extended-release approved for children aged ≥ 10 years. Avoid use in children under 2 years due to risk of hepatotoxicity. 2 Hospital Physician Board Review Manual www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 2. Drug Selection for New Seizure Diagnosis Seizure Type First-line AED Medications to Avoid Generalized tonic-clonic Carbamazepine, lamotrigine, oxcarbazepine, topiramate, valproate If juvenile myoclonic epilepsy is suspected, or absence seizures: carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, vigabatrin Focal seizures Absence Carbamazepine, lamotrigine, oxcarbazepine, phenobarbital, phenytoin, topiramate, valproate Ethosuximide, lamotrigine, valproate Myoclonic Levetiracetam, valproate, topiramate Tonic or atonic Valproate A recent study by Brodie and colleagues8 has provided additional insight into how patients respond to medications prescribed initially after a new diagnosis of epilepsy. They followed 1098 newly diagnosed patients for a median duration of 7.5 years. Causes of epilepsy were idiopathic for 23%, symptomatic for 41%, and cryptogenic for 35%. Their analysis revealed that 4 patterns emerge: early and sustained seizure freedom (37%), delayed and sustained seizure freedom (22%), fluctuation between periods of seizure freedom and relapse (16%), and never seizure-free for any complete year (25%).8 Selecting an Agent An initial medication is selected based on the patient's seizure type or syndrome (Table 2). Joint statements from American Academy of Neurology and American Epilepsy Society,9,10 and most recently from the NICE guidelines from the United Kingdom, also provide guidance on selecting medications for various seizure syndromes.11 Once the seizure type or syndrome has been determined, other patient-specific factors should be taken into consideration. These include age, health Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, vigabatrin Carbamazepine, gabapentin, oxcarbazepine, phenytoin, pregabalin, tiagabine, vigabatrin Carbamazepine, gabapentin, oxcarbazepine, pregabalin, tiagabine, vigabatrin conditions, concurrent medications, medication insurance coverage and cost considerations, and the patient’s ability and preference to take the medication as prescribed. An understanding of the pharmacokinetic properties of the various AEDs is useful to differentiate the medications available. Table 3 summarizes typical dosing for AEDs. Subsequent Therapy If the first prescribed AED does not adequately control seizures, a second medication should be considered. There is adequate data to support the newer AEDs as adjunctive treatment.9,10 Ideally, the first medication should remain at the current (and/or tolerated) dose, while the second medication is titrated up to a therapeutic dose.12 Once the new drug is at steady-state, the first medication can be tapered off, depending on how the patient is responding to the new regimen. If the first AED resulted in a treatment emergent side effect, such as a significant rash or other hypersensitivity reaction, discontinuing it immediately is likely the most appropriate action. A second AED could be initiated with an oral or intravenous loading dose to provide adequate seizure protection. www.turner-white.comEpilepsy Volume 1, Part 6 3 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 3. Dosing of Antiepileptic Drugs Drug Dosage Forms Available Strengths Typical Oral Dosing Range and Frequency Carbamazepine (Carbatrol, Tegretol,Tegretol XR) Capsule (ER) Oral suspension Tablet (IR) Chewable tablet Tablet (ER) Tablet 100, 200, 300 mg 100 mg/5 mL 200 mg 100 mg 100, 200, 400 mg 5, 10, 20 mg Child (initial, monotherapy): 5–10 mg/kg/day Adult (initial, monotherapy): 5 mg/kg/day Child (typical maintenance): 10–40 mg/day Adult (typical maintenance): 1000–2000 mg/day Clonazepam (Klonopin) Tablet ODT 0.5, 1, 2 mg 0.125, 0.25, 0.5, 1, 2 mg Diazepam (Diastat) Rectal gel Oral solution 2.5, 5, 7.5, 10, 12.5, 15, 20 mg 5 mg/5 mL Divalproex (Depakote) Capsule (sprinkle) Tablet (ER) Tablet (DR) 125 mg 250, 500 mg 125, 250, 500 mg Ethosuximide (Zarontin) Capsule Oral solution 250 mg 250 mg/5 mL Clobazam (Onfi) 4 Hospital Physician Board Review Manual Adult/Child age ≥2 years >30 kg (adjunct): Initially 10 mg orally daily (in 2 divided doses), titrating to 20 mg daily (in 2 divided doses) on day 7 and to 40 mg daily (2 divided doses) on day 14 Adult/Child age ≥2 years ≤30 kg (adjunct): Initially 5 mg orally daily (in 2 divided doses), titrating to 10 mg daily (2 divided doses) on day 7 and to 20 mg daily (2 divided doses) on day 14 Adult: 0.5 mg orally TID initially; may increase daily dose by 0.5–1 mg orally every 3 days to a maximum total daily dose of 20 mg (in 3 divided doses) Child (up to age 10 years, or 30 kg): Initially 0.01–0.03 mg/kg/day orally divided into 2 to 3 daily doses; may increase by 0.25–0.5 mg every 3 days to a maximum total daily dose of 0.1–0.2 mg/kg/day (in 3 divided doses) Adult (adjunct): 2–10 mg orally BID–QID Adult (adjunct): 0.2 mg/kg rectally (round up to available rectal dose); may repeat in 4–12 hours, no more than 1 episode every 5 days, and 5 episodes per month Child: varies by age and severity; refer to PI Adult (adjunct): 10–15 mg/kg/day orally; may increase dosage 5–10 mg/kg/wk to achieve optimal clinical response (maximum 60 mg/kg/day or less with a therapeutic range of 50–100 µg/mL) Child age 10–18 years (adjunct): 10–15 mg/kg/day orally; may increase dosage 5–10 mg/kg/wk to achieve optimal clinical response (maximum 60 mg/kg/day or less with a therapeutic range of 50–100 µg/mL) Adult (absence seizure): 500 mg orally adjusted by 250-mg increments every 4–7 days to desired therapeutic effect (doses >1.5 g/day must be supervised by the patient’s physician) Child age 3–6 years (absence seizure): 250 mg orally daily, increase daily dose by 250 mg every 4–7 days as needed (doses >1.5 g/day must be supervised by the patient’s physician) Child age >6 years (absence seizure): 500 mg orally daily; increase daily dose by 250 mg every 4–7 days as needed (doses >1.5 g/day must be supervised by the patient’s physician) (continued on page 5) www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 3. Dosing of Antiepileptic Drugs (continued) Drug Dosage Forms Available Strengths Typical Oral Dosing Range and Frequency Ezogabine (Potiga) Tablet 50, 200, 300, 400 mg Felbamate (Felbatol) Tablet Oral suspension 400, 600 mg 600 mg/5 mL Gabapentin (Neurontin) Capsule Oral solution Tablet 100, 300, 400 mg 250 mg/5 mL 100, 300, 400, 600, 800 mg Lacosamide (Vimpat) Tablet Oral solution Injection solution 50, 100, 150, 200 mg 10 mg/mL 10 mg/mL Lamotrigine (Lamictal) Tablet (IR) Tablet (ER) Chewable tablet ODT Tablet Oral solution Tablet (ER) 25, 100, 150, 200 mg 25, 50, 100, 200 mg 2, 5, 25 mg 25, 50, 100, 200 mg 250, 500, 750, 1000 mg 100 mg/mL 500, 750 mg Adult (age ≥18 years, adjunct): Start with 100 mg TID for 1 week; increase to maintenance dose at weekly intervals by no more than 150 mg/day; optimal effective dose between 200 mg TID to 400 mg TID Child age 2–14 years (Lennox-Gastaut): 15 mg/kg/day in 3 to 4 divided doses; increase by 15 mg/kg/day increments at weekly intervals; maximum dose of 45 mg/kg/day or 3600 mg/day (whichever is less) Adult/Child 14+ years (initial): 1200 mg/day in 3 to 4 divided doses; may increase in 600-mg increments every 2 weeks to 2400–3600 mg/day Adult (maintenance): 3600 mg/day Adult (adjunct): 300 mg TID; may increase up to 1800 mg/ day in divided doses Child age 3–12 years (initial): 10–15 mg/kg/day in 3 divided doses Child age 3–4 years (maintenance): Titrate upwards over 3 days to 40 mg/kg/day in 3 divided doses Child age 5–12 years (maintenance): Titrate upwards over 3 days to 25–35 mg/kg/day in 3 divided doses Adult age 17+ years (adjunct): Oral, IV: start with 50 mg orally BID, and increase by 50 mg BID every week to an initial therapeutic dose of 100 mg BID; maximum recommended dose is 200 mg BID; when switching from oral to IV formulations, the total daily dose and frequency should be the same; IV therapy should only be used temporarily Dose depends on presence of valproic acid or enzymeinducing AED and type of seizure; refer to PI Tablet Oral suspension Tablet (ER) 150, 300, 600 mg 300 mg/5 mL 150, 300, 600 mg Levetiracetam (Keppra, Keppra XR) Oxcarbazepine (Trileptal, Oxtellar) Adult (adjunct): Start with 500 mg orally BID; increase daily doses by 1000 mg every 2 weeks; target of 3000 mg/day Child: Dose varies by type of seizure and age; refer to PI Adult age 16+ years (adjunct): Initial dose of 1000 mg once daily; may be adjusted in increments of 1000 mg every 2 weeks to a maximum recommended daily dose of 3000 mg Adult (initial): 300 mg BID Adult (maintenance): 600 mg BID Child age 2–4 years (adjunct): 8–10 mg/kg/day in 2 divided doses; consider using 16–20 mg/kg/day divided in 2 divided doses if weight <20 kg Child age 4–16 years (initial conversion): 8–10 mg/kg/day in 2 divided doses Child age 4–16 years (target maintenance): range depends on patient weight (continued on page 6) www.turner-white.comEpilepsy Volume 1, Part 6 5 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 3. Dosing of Antiepileptic Drugs (continued) Drug Dosage Forms Available Strengths Typical Oral Dosing Range and Frequency Perampanel (Fycompa) Tablet 2, 4, 6, 8, 10, 12 mg Phenobarbital (Luminal) Oral elixir Tablet Initial: 2 mg once daily at betime, if patient is not on enzyme inducer; 4 mg once daily at bedtime, if patient is on enyzme-inducing AED; may increase by a maximum of 2 mg daily every week (or 2 weeks) to a maximum of 12 mg once daily Adult (maintenance): 50–100 mg orally BID–TID Child (maintenance): 15–50 mg orally BID–TID Phenytoin (Dilantin, Phenytek) Pregabalin (Lyrica) Capsule (ER) Capsule (IR) Oral suspension Chewable tablet Capsule Primidone (Mysoline) Tablet Rufinamide (Banzel) Tablet Oral suspension Tiagabine (Gabitril) Tablet 20 mg/5 mL 15, 16.2, 30, 32.4, 60, 64.8, 97.2, 100 mg 30, 100, 200, 300 mg Due to wide interindividual variability in metabolism and absorption, regimen must be individualized 100 mg 100 mg/4 mL, 125 mg/5 mL 50 mg 25, 50, 75, 100, 150, 200, Adult (adjunct): Initial dose no greater than 75 mg orally 225, 300 mg BID or 50 mg orally TID (150 mg/day) and increase to a maximum dose of 600 mg/day in divided doses (BID or TID) based on response and tolerability Children: Safety and efficacy not established 50, 250 mg Adult age 8+ years (adjunct or monotherapy): 100–125 mg orally every night for 3 days, then increase dose by 100–125 mg/day (divided doses) every 3 days to reach a dose of 250 mg TID–QID Child age <8 years (adjunct or monotherapy): 50 mg orally every night for 3 days, then increase dose by 50 mg/day (divided doses) every 3 days to reach a dose of 125–250 mg TID 200, 400 mg Adult: Initial dose of 400–800 mg/day in 2 equally divided doses and increase by 400–800 mg/day every 2 days 40 mg/mL until a maximum of 3200 mg/day in 2 equally divided doses is reached Children age 4+ years: Initial dose of 10 mg/kg/day in 2 equally divided doses and increase by 10 mg/kg increments every other day to a target dose of 45 mg/kg/day or 3200 mg/day, whichever is less, administered in 2 equally divided doses 2, 4, 12, 16 mg Adult (adjunct): 4 mg orally daily; may increase dosage by 4–8 mg/day at weekly intervals to a maximum dose of 56 mg/day (in 2–4 divided doses) Child age 12–18 years (adjunct, with enzyme-inducing AEDs): 4 mg orally daily; may increase dosage by 4 mg/ day after 7 days, then total daily dose may be increased by 4–8 mg/day at weekly intervals to a maximum dose of 32 mg/day (in 2–4 divided doses) (continued on page 7) 6 Hospital Physician Board Review Manual www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 3. Dosing of Antiepileptic Drugs (continued) Drug Dosage Forms Available Strengths Typical Oral Dosing Range and Frequency Topiramate (Topamax) Capsule (sprinkle) Tablet 15, 25 mg 25, 50, 100, 200 mg Valproic acid (Depakene) (Stavzor) Capsule Oral syrup Capsule (DR) 250 mg 250 mg/5 mL 125, 250, 500 mg Vigabatrin (Sabril) Powder for oral solution 500 mg/packet Tablet 500 mg Zonisamide (Zonegran) Capsule Adult and child age >2 years (initial monotherapy): 25 mg orally BID (am and pm); may increase each dose by 25 mg weekly; maximum dose of 200 mg orally BID Adult (adjunct): 25–50 mg/day orally; may increase dosage by 25–50 mg/day at 1-week intervals to the usual maintenance dose of 200–400 mg/day in 2 divided doses Child age 2–16 years (adjunct): Start with maximum 25 mg (range of 1–3 mg/kg/day) orally at bedtime for the first week, then increase by 1–3 mg/kg/day (in 2 divided doses) at 1–2 week intervals to the usual effective dosage of 5–9 mg/kg/ day Adult (adjunct): 10–15 mg/kg/day orally (in 2–3 divided doses if total daily dose >250 mg); may increase dosage 5–10 mg/kg/week to achieve optimal clinical response (maximum 60 mg/kg/day or less with a therapeutic range of 50–100 µg/mL) Child age 10–18 years (adjunct): Dose as an adult Child age <10 years: Safety and efficacy not established Adult (adjunct): 500 mg BID; may increase dosage by 500 mg/day at 1-week intervals to the usual maintenance dose of 1500 mg BID Child age 1 month–2 years (infantile spasms): Initial dose of 50 mg/kg/day (in 2 divided doses); can titrate 25–50 mg/ kg/day every 3 days to maximum dose of 150 mg/kg/day Age 16+ years (adjunct): 100 mg/day orally; may increase dosage by 100 mg/day every 2 weeks to the usual effective dosage range of 100–600 mg/day in 1 to 2 divided doses; no additional benefit seen with doses >400 mg/day 25, 50, 100 mg AED = antiepileptic drug; BID = twice daily; DR = delayed release; ER = extended release; IR = immediate release; ODT = orally disintegrating tablet; PI = package insert; QID = 4 times daily; TID = 3 times daily. Toxicity Side Effects In the case of AEDs, side effects are concentrationrelated, idiosyncratic, or due to chronic exposure. Table 4 provides a summary of side effects for the various agents. Concentration-related side effects result from an exaggeration of the pharmacologic effects of a medication.13 Sedation, ataxia, and headache are examples. These side effects generally are reversible with a dose reduction. It may be difficult to achieve the fine balance between con- trolling seizures and side effects for some patients, and multiple trials of different medications may be necessary. Some patients remain on AEDs for decades, and chronic exposure side effects must be considered. Some chronic effects impact weight. Valproic acid is highly associated with weight gain, as are gabapentin and pregabalin, while topiramate and zonisamide are associated with weight loss.14–16 Bone health and the impact of AEDs on bone density have been of great concern over www.turner-white.comEpilepsy Volume 1, Part 6 7 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 4. Adverse Effects of Antiepileptic Drugs Acute Side Effects Drug Carbamazepine Clobazam Divalproex Ethosuximide Ezogabine Felbamate Gabapentin Lacosamide Lamotrigine Levetiracetam Oxcarbazepine Perampanel Phenobarbital Concentration-Dependent Idiosyncratic Diplopia, dizziness, drowsiness, Blood dyscrasias, rash nausea, unsteadiness, lethargy Common side effects: somnolence or sedation, drooling, constipation, cough, urinary tract infection, aggression, insomnia, dysarthria, fatigue Tremors, unsteadiness Hepatic failure, pancreatitis Ataxia, drowsiness, GI distress, Blood dyscrasias, rash unsteadiness, hiccoughs Common side effects: dizziness, fatigue, confusion, hallucination, vertigo, tremor, problems with coordination, double vision, problems paying attention, memory impairment, lack of strength, urinary retention, QT prolongation Anorexia, nausea, vomiting, insomnia, Aplastic anemia, acute hepatic failure headache Dizziness, fatigue, somnolence, Pedal edema ataxia Dizziness, nausea, fatigue, ataxia, Not established abnormal vision, diplopia, vertigo, and nystagmus Diplopia, dizziness, unsteadiness, Rash headache Sedation, behavioral disturbance Not established Sedation, dizziness, ataxia, nausea Rash Dizziness, somnolence, fatigue, Not established irritability, falls, nausea, weight gain, veritgo, ataxia, gait distrubance, and balance disorder, hostility and aggression Ataxia, hyperactivity, headache, unBlood dyscrasias, rash steadiness, sedation, nausea the past decade. Unfortunately, it is not entirely clear which AEDs decrease bone density and what the mechanism of bone loss is. In the case of the enzyme-inducing AEDs (carbamazepine, phenytoin, phenobarbital), it is thought that induction 8 Hospital Physician Board Review Manual Chronic Side Effects Hyponatremia Not established CNS depression Behavior changes, headache Not established Not established Weight gain, breast enlargement Not established Not established Not established Hyponatremia, hemic and lymphatic system (bone marrow depression, agranulocytosis, aplastic anemia, pancytopenia, neutropenia), pancreatitis, and/or lipase and/or amylase increase, metabolism and nutrition disorders (folic acid deficiency) Not established Behavior changes, connective tissue disorders, intellectual blunting, metabolic bone disease, mood change, sedation (continued on page 9) of vitamin D metabolism could be responsible, but research has not consistently demonstrated this.17,18 While the data are not entirely conclusive, it is appropriate to ensure that patients are consuming adequate amounts of calcium and vitamin D. www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Table 4. Adverse Effects of Antiepileptic Drugs (continued) Acute Side Effects Drug Concentration-Dependent Idiosyncratic Chronic Side Effects Phenytoin Ataxia, nystagmus, behavior changes, dizziness, headache, incoordination, sedation, lethargy, cognitive impairment, fatigue, visual blurring Blood dyscrasias, rash, immunologic reaction Primidone Behavior changes, headache, nausea, sedation, unsteadiness Blood dyscrasias, rash Pregabalin Dizziness, somnolence, blurred vision Pedal edema, creatine kinase elevation, decreased platelets Common side effects: nausea, vomiting, dizziness, headache, somnolence, and fatigue Dizziness, fatigue, difficulty concenSpike-wave stupor trating, nervousness, tremor, blurred vision, depression, weakness Difficulty concentrating, psychomotor Metabolic acidosis, acute angle glaucoma, oligohidrosis slowing, speech or language problems, somnolence/fatigue, dizziness, headache GI upset, sedation, unsteadiness, tremor, thrombocytopenia Behavior changes, cerebellar syndrome, connective tissue changes, skin thickening, folate deficiency, gingival hyperplasia, hirsutism, coarsening of facial features, acne, cognitive impairment, metabolic bone disease, sedation Behavior change, connective tissue disorders, cognitive impairment, sedation Weight gain Rufinamide Tiagabine Topiramate Valproic Acid Vigabatrin Zonisamide Common side effects: somnolence, fatigue, weight increase, blurred vision, nystagmus, tremor, memory impairment, arthralgia, abnormal coordination, confusion Sedation, dizziness, cognitive impair- Rash, oligohydrosis ment, nausea The body of evidence showing that the enzymeinducing AEDs have a negative effect on cholesterol levels and cardiac risk factors is growing, and the patient’s risk for cardiac events should also be considered when prescribing an AED.19–21 Idiosyncratic reactions are the most worrisome of the side effects. These reactions are unpredictable and can range from minor (pedal edema) to life-threatening, including hepatic failure and angranulocytosis. When these reactions occur, discontinuation of the offending agents is almost Not established Not established Kidney stones, weight loss, hyperesthesia Polycystic ovary–like syndrome (possible), weight gain, hyperammonemia, menstrual cycle irregularities Not established Kidney stones, weight loss always required.22 Recently, there has been progress identifying genetic causes of drug reactions. Patients who carry the HLA-B*1502 allele are at high risk to develop severe cutaneous drug reactions when exposed to carbamazepine and phenytoin. This allele is significantly more prevalent in patients of Asian descent.23 The FDA recommends genetic testing in patients of Asian descent before initiating carbamazepine. Anticonvulsant hypersensitivity and drug reaction with eosinophilia and systemic symptoms (DRESS) are different www.turner-white.comEpilepsy Volume 1, Part 6 9 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection terms for essentially the same clinical diagnoses and are reported with several AEDs. Symptoms include hematologic abnormalities, other organ involvement including liver dysfunction, and skin rash.24 With the exception of the genetic testing for carbamazepine, there are no laboratory tests that can predict which patients are likely to develop hypersensitivity reactions. Once a patient experiences a hypersensitivity reaction, a new medication must be selected cautiously as cross-reactivity may occur. There is evidence that cross-reactivity occurs between the aromatic AEDs, phenytoin, carbamazepine, and oxcarbazepine approximately 30% of the time.25 Teratogenicity Determining if a medication causes birth defects is a complex research question. It is critical to collect data prospectively and with a large enough sample size to truly capture whether exposure to medications increases the risk of birth defects. The literature is also challenging to interpret because of variability in how research groups have tracked and defined what they reported as birth defects. In the past 12 months, several groups have published data that are helping better characterize the teratogenicity of AEDs. The North American Pregnancy Registry recently analyzed 4899 women on AED monotherapy and 442 women with epilepsy and no AED exposure.26 The AEDs associated with higher risk of birth defects compared to unexposed patients were topiramate, valproate, and phenobarbital. This analysis did not detect any correlation of birth defects to doses of AEDs. An analysis of data from 3909 women on monotherapy carbamazepine, lamotrigine, valproic acid, or phenobarbital from the EURAP database did demonstrate increased risks of malformations based on dose of AEDs.27 The reference group was women on lamotrigine taking less 10 Hospital Physician Board Review Manual than 300 mg/day. AED doses that had statistically higher odds for major congenital malformations were: carbamazepine >1000 mg/day, phenobarbital ≥150 mg/per day, valproic acid ≥700 to <1500 mg per day, and valproic acid ≥1500 mg per day. Data on the newer medications is lacking in this data set. A recent report from Denmark examined 1532 pregnancies (of 837,795 live births, nationally) exposed to lamotrigine, oxcarbazepine, topiramate, gabapentin, or levetiracetam.28 They found no difference between the infants exposed versus the infants not exposed. The numbers of infants exposed to individual medications was quite low, and that limited the ability to detect if certain medications are more problematic. These new studies help clarify that monotherapy is best at the lowest dose possible. The Neurodevelopmental Effects of Antiepileptic Drugs (NEAD) study group is investigating the effects of monotherapy AED exposure during pregnancy on children. There were enough women taking carbamazepine, lamotrigine, phenytoin, and valproate monotherapy to further investigate the impact of those medications on children at age 3 years.29 This study found that, while controlling for maternal IQ, the children exposed to valproate had statistically significantly lower IQs.29 A further analysis of verbal and nonverbal abilities determined that children exposed to valproate had lower scores as compared to the other AEDs.30 Additionally, the verbal abilities for each of the AED-exposed groups were lower than the normative data. The investigators followed-up with the children at age 4.5 years and found that the differences persist: children exposed to valproate have reduced IQs and all 4 AED exposure groups have reduced verbal abilities.31 Pre-pregnancy planning discussions with women should include balancing the risks of seizures with www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection possible medication effects, and valproate should be avoided if possible. Folic acid supplementation should be initiated prior to conception at a dose of at least 0.4 µg/day.32 Consultation and monitoring by an obstetrician is recommended.33 For women who are not planning conception, ensuring they are using adequate contraception is critical. Many AEDs interact with hormonal contraceptives, regardless of the route of delivery, including implants, patches, and vaginal rings.34 Patient education is crucial, so that the risks engendered by unplanned pregnancies are minimized. First-generation drugs Generally, the first-generation AEDs all undergo hepatic metabolism. The majority of them are highly bound to protein, they are all involved in numerous drug interactions, and most exhibit nonlinear pharmacokinetics. Acetazolamide Acetazolamide is a carbonic anhydrase inhibitor that has acedotally been used to treat catamenial epilepsy.37 Benzodiazepines Suicidality All prescribers should be aware of the FDA warning issued in 2008 regarding suicidal behavior and ideation and AEDs.35 This warning was based on a meta-analysis of pooled data from 199 clinical trials of carbamazepine, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, valproate, and zonisamide. The FDA has applied the warning to all AEDs, even those not included in this analysis. There is debate among the epilepsy community as to whether this warning is appropriate and warranted.36 Regardless, depression is not uncommon in patients with epilepsy, and prescribers should discuss mood and assess for adverse effects of AEDs. Summary of Antiepileptic drugs Information comparing or contrasting the various AEDs is summarized in Table 3 and Table 4. Here, notable aspects of the various medications are discussed. For information about the pharmacokinetic characteristics of AEDs, refer to the previous article in this series (Epilepsy Board Review Manual, Volume 1, Part 5). 12 Hospital Physician Board Review Manual Benzodiazepines are freqently used to treat cluster seizures or prolonged seziures. Lorazepam and diazepam are available as intravenous solutions, oral solutions (intensols), and tablets. Additionally, diazepam is available as a rectal gel for home treatment of cluster seizures.38 It is currently under investigation for intramuscular delivery via an autoinjector.39 These medications are usually dosed intermittently and reserved as rescue therapy aimed at preventing emergency department visits or hospitalization. There is increasing evidence that midazolam delivery intramuscularly in the ambulance has comparable efficacy to intravenous lorazepam at prehosptial seizure cessation.40 An intranasal delivery formula of midazolam is also under investigation as an alternative to rectal diazepam.41 Clonazepam is indicated for daily, regular dosing for myoclonic, akinetic, and Lennox-Gastaut seizures, but tolerance develops and loss of efficacy may occurr.42 Carbamazepine Carbamazepine induces its own hepatic clearance (autoinduction) and has an active metabolite (carbamazepine-10, 11-epoxide) that also exerts some antiseizure effects.43,44 Carbamazepine's primary metabolic pathway is CYP 3A4, which is www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection responsible for metabolizing numerous medications. Carbamazepine causes enzyme induction, resulting in many drug interactions.45 The efficacy of carbamazepine has been demonstrated in many studies. A Veterans Affairs Epilepsy Cooperative study demonstrated that it was as efficacious as phenytoin, phenobarbital, and primidone, but better tolerated than phenobarbital and primidone.46 A subsequent VA study demonstrated that carbamazepine was better at controlling focal seizures and better tolerated than valproic acid.47 Most recently, carbamazepine was shown to be as efficacious as lamotrigine and gabapentin but not as well tolerated in an elderly veteran population with new-onset seizures.48 Ethosuximide Ethosuximide is primarily indicated to treat absence seizures, which usually begin in childhood. In a recent study that compared ethosuximide, valproic acid, and lamotrigine, both ethosuximide and valproic acid demonstrated similar efficacy for absence seizures, but ethosuximide was better tolerated.49 Phenobarbital Phenobarbital has been used as an anticonvulsant for a century. It was introduced to market prior to the FDA requiring medications to be approved based on evidence of efficacy. It has an extremely long half-life (72–124 hours) and is extensively metabolized through the liver. It does, however, have a linear dose/concentration relationship. It also causes induction of hepatic enzymes, resulting in numerous drug interactions. Its use is limited by side effects, including sedation and cognitive impairment.50 It had been used in the past to treat febrile seizures in children, but concern about lower IQs and lack of impact on later seizures has reduced its use.51 Phenytoin Phenytoin is unusual due to its saturable, nonlinear metabolism, resulting in greater than expected blood concentrations when increasing doses. Depending on the patient, very small increases in dose (10%–30%) can cause a greater than doubling of the blood concentration.52 The primary metabolic pathways are CYP 2C9 and 2C19. The CYP 2C9 pathway becomes saturated first, and then the CYP 2C19 pathway becomes involved. Several polymorphisms of CYP 2C9 and 2C19 have been identified,53 but there is no current recommendation to routinely test patients prior to initiating phenytoin treatment. This leads to substantial interpatient variability and unpredictability between dose and concentration. Prescribers must be cautious when adjusting doses because small (10%–20%) changes can potentially result in very large changes in blood levels and side effects. Intravenous phenytoin has a pH of 11 and is incompatible in many intravenous solutions. It must be infused no faster than 50 mg/min, and patients should have electrocardiographic monitoring for potential arrhythmias.54 Fosphenytoin is a pro-drug of phenytoin and is rapidly hydrolyzed by phosphatases into phenytoin. This allows for a better tolerated intravenous formulation that can be delivered more quickly and safely. It can also be administered intramuscularly if necessary.55 Primidone Primidone is metabolized into 2 active metabolites: phenylethylmalonamide and phenobarbital. As a result, it has a side effect and drug interaction profile similar to phenobarbital. While primidone was first clinically used in 1952, the study that established its efficacy was the VA Cooperative Study that compared primidone to carbamazepine, phenytoin, and phenobarbital.50 www.turner-white.comEpilepsy Volume 1, Part 6 13 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection Valproic Acid Valproic acid is available in many formulations, requiring the prescriber to be vigilant that the product desired is the one prescribed (and dispensed from the pharmacy). Valproic acid is available as syrup, a liquid-filled capsule, and a delayed-release capsule. To overcome the frequent gastrointestinal upset, it is also available as divalproex sodium (2 valproic acid molecules bound to sodium), which dissociates into valproic acid. It is available as a sprinkle, an enteric-coated tablet (delays medication release until after passing through the stomach), and an extended-release tablet (designed to release the medication over 24 hours). It is also important to note that the extended-release formulation is not equivalent to the enteric-coated formulation. Only 80% to 90% of the dose in the extendedrelease formulations is released.56 The intravenous formulation is valproate sodium, the sodium salt form of valproic acid. While valproic acid is a broadspectrum AED and used for several seizure types, it is less frequently being recommended for use in women with child- bearing potential (see Teratogenicity section). As valproic acid doses increase, the protein binding sites saturate, resulting in a less than expected increase in blood concentrations as the doses get higher.57 metabolite can accumulate in patients who have lower levels of functional CYP 2C19 enzyme, and they should be started on lower doses.59 Felbamate In 1993, felbamate was the first new AED to be approved in 15 years. During the first 12 to 18 months of use, cases of aplastic anemia (33 patients) and hepatic failure (18 patients) were reported. This has resulted in felbamate being reserved for patients whose seizures remain uncontrolled despite multiple trials of AEDs in which the benefit of adding felbamate outweighs the risks.60 Liver function tests and hematologic evaluations should be done as clinically appropriate. It was investigated in patients with focal seizures61–63 and seizures associated with Lennox-Gastaut syndrome.64,65 Gabapentin The first AED that did not interact with other medications was gabapentin. Its use as an AED is limited by a short half-life that requires frequent dosing (3 to 4 times a day) to maintain consistent exposure. It is completely eliminated from the body through the kidneys. As patients age and their kidney function declines, the interval between doses can be extended.66 Second-generation drugs Lamotrigine The second- (and third-) generation AEDs offer new mechanisms of action, fewer drug interactions, and different adverse effect profiles as compared to the first-generation agents. Lamotrigine is notable for its significant drug interaction with valproic acid and for potentially increasing the risk of developing a severe rash.67 The half-life of lamotrigine with no interacting medications is approximately 25 hours. Valproic acid inhibits the clearance of lamotrigine, resulting in an increase in the half-life (~70 hrs), while enzymeinducers (phenytoin, carbamazepine, phenobarbital) increase the clearance, resulting in a decrease in the half-life (~12 hrs).68 This requires conservative Clobazam Clobazam has been used internationally for 30 years, but only recently has received FDA approval. It is a benzodiazepine indicated for use in patients with Lennox-Gastaut syndrome.58 The 14 Hospital Physician Board Review Manual www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection lamotrigine dosing when adding it to a regimen that contains valproic acid. If a patient currently taking lamotrigine requires the addition of valproic acid, the patient should be closely monitored and a significant dose reduction of lamotrigine will likely be required. Relatively low doses of valproic acid have been shown to significantly inhibit lamotrigine.69 Beyond the use of lamotrigine as adjunctive treatment for focal seizures, there is evidence that lamotrigine is efficacious as adjunctive treatment for primary generalized seizures70 and as monotherapy treatment for focal or primary generalized seizures.71 It can also be considered for treatment of juvenile myoclonic epilepsy,72 particularly in women with child-bearing potential. Lamotrigine is approved for conversion to monotherapy by the FDA. Oxcarbazepine is an analog of carbamazepine that is approved for montherapy use by the FDA. It is rapidly metabolized to an active metabolite, the monohydroxylated derivative (MHD). If monitoring of blood levels is desired, the MHD level should be measured. Oxcarbazepine does not induce liver enzymes to the same extent as carbamazepine, resulting in less clinically significant drug interactions.76 Hyponatremia can occur and may result in discontinuation of the medication.77 If a patient had a hypersensitivity reaction to carbamazepine, there is a 25% to 30% risk that a hypersensitivity reaction will occur with oxcarbazepine.78 There is evidence to support oxcarbazepine being prescribed as either monotherapy or adjunctive therapy for focal seizures for both adults and children.79–81 Levetiracetam Pregabalin The second AED that does not interact with other medications is levetiracetam. It has become one of the first-line agents because of its convenient dosing (twice a day) and decreasing cost since becoming available generically several years ago. Its use is limited by its side effects. A recent report of patients enrolled in open-label, long-term follow-up found that the most common side effects resulting in discontinuation were depression, insomnia, anxiety, and nervousness.73 Levetiracetam is frequently used as monotherapy clinically. A meta-analysis from 2011 concluded there is adequate data to support adjunctive use, but there was not enough data to support monotherapy.74 A recent prospective, open-label, randomized, multicenter study that compared lamotrigine and levetiracetam monotherapy in newly diagnosed patients, with either focal or generalized seizures, showed no difference in efficacy or tolerability between the medications.75 Pregabalin is the third AED that does not interact with other medications. It is primarily used for neuropathic pain due to shingles, fibromyalgia, diabetes, and spinal cord injuries. Approximately 90% of a dose is eliminated in the urine unchanged. A recent meta-analysis of pregabalin monotherapy data determined there was no available data assessing pregabalin use in patients with generalized tonic-clonic seizures.82 The limited data assessing monotherapy for focal seizures show similar tolerability as compared to lamotrigine and slightly less efficacy, but there were study design limitations.83 Oxcarbazepine Rufinamide The clearance of rufinamide is increased by the enzyme-inducers (phenytoin, carbamazepine, phenobarbital) and inhibited by valproic acid. The mechanism of the interaction with valproic acid is not entirely clear.84 The molecule is insoluble in www.turner-white.comEpilepsy Volume 1, Part 6 15 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection water and dissolution is slow and erratic, resulting in lower bioavailability for the higher strength tablets.85 The FDA approval was based on 138 subjects with generalized seizures with LennoxGastaut.86 An additional study of patients with focal seizures demonstrated efficacy, but to a smaller magnitude compared to the previous study.87 es and efficacy. Patients must also enroll with the program for safety monitoring and to obtain the medication. The new guidelines for infantile spasms place vigabatrin after adrenocorticotropic hormone as the only 2 medications with evidence of efficacy.1 Zonisamide Tiagabine Clinical experience with tiagabine has resulted in a number of reports of tiagabine-induced nonconvulsive status epilpeticus.88–90 In 2005 the FDA issued a warning about seizures in patients taking tiagabine for non–seizure-related reasons.91 This has resulted in very limited prescribing for primary generalized seizures, and data supports use as an add-on treatment in refractory partial onset seizures.9,10 Topiramate Topiramate is notable for its effects on cognition, including word finding difficulty.92 Weight loss, kidney stones, and paresthesias can also occur with topiramate treatment. It has multiple mechanisms of action and also is indicated for migraine prophylaxis and weight loss (in combination with phentermine). There is evidence to support monotherapy use for both focal and primary generalized tonic-clonic seizures.93 Vigabatrin While vigabatrin has been used internationally for about 35 years, due to visual field defects and potentially permanent vision changes, vigabatrin is subject to a risk evaluation and mitigation strategy through the FDA.94,95 Vigabatrin is only available through the manufacturer via the Share program, which requires prescribers to register and work with the manufacturer to monitor for vision chang16 Hospital Physician Board Review Manual Zonisamide is a multi-mechanism AED with weak carbonic anhydrase inhibition that shares a very similar side effect profile with topiramate. Additionally, if patients are allergic to sulfa medications, zonisamide should not be prescribed. It has a very long half-life, which may be preferable for patients who have difficulty taking medications more than once a day.96 Initially, the higher than expected rates of renal calculi in clinical studies resulted in delaying zonisamide’s development in the United States;97 however, additional studies provided evidence that the rates were not excessively high.98,99 Third-generation drugs Ezogabine While ezogabine was under investigational studies, its generic name was retigabine; that is still the generic name approved by the European Union. Ezogabine brings a new mechanism of action to the AED choices as a potassium channel agonist.100 Unlike other AEDS, ezogabine exerts an effect on urinary bladder muscles and causes urinary retention.101 Current evidence supports adjunctive therapy for focal seizures.102,103 Lacosamide Lacosamide is also free of significant drug interactions with other AEDs. Its mechanism of action is attributed to slow inactivation of sodium channels.104 Lacosamide was studied with total daily www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection doses of 200, 400, and 600 mg.105 In this study, efficacy was seen with the 200-mg and 400-mg doses, but without additional response at the 600mg dose. Side effects were greater at the 600-mg dose. An additional study compared 200 mg versus 400 mg and found no difference in efficacy between the doses.106 A third study compared 400 mg versus 600 mg and demonstrated they were similarly efficacious.107 Post hoc analysis of the clinical trials indicates that lacosamide is best tolerated when used in combination with non–sodium channel blocking AEDs. Patients did not tolerate higher dosages of lacosamide when also taking phenytoin, carbamazepine, oxcarbazepine, and lamotrigine.108 Perampanel As a recently approved AED, perampanel has a unique mechanism of action as the first AMPA inhibitor reducing the action of glutamate.109 It is also notable for its long half-life, which enables once-daily dosing.109 Three clinical trials have been conducted evaluating a variety of doses.110–112 While a new mechanism of action provides options for patients, perampanel appears to have some significant psychiatric effects that will require close monitoring, including aggression, hostility, irritability, and anger.113 Other considerations Many of the AEDs are now available as generic products. There is much concern that generic AEDs are not truly equivalent to the innovator products. The American Academy of Neurology has issued a statement that opposes AED substitution without prescriber consent.114 Bioequivalence is determined by the rate and extent a generic medication is absorbed as compared to the innovator formulation. Generally, these studies are conducted as single-dose fed and fasting randomized cross-over (and occasionally multiple-dose) studies in healthy adults. If the rate and absorption 90% confidence intervals are within 80% to 125% of the innovator product, they are determined to be bioequivalent (FDA guidance). Most of the data to date indicating that there may be problems with switching from branded AEDs to a generic is observational and lacks the rigor of a randomized, placebo-controlled clinical study design. A 2010 meta-analysis found only 9 randomized controlled trials that were available for their analysis, and all were published between 1986 and 1997.115 The Agency for Healthcare Research Quality conducted a comparative effectiveness review to examine the data surrounding effectiveness and safety of antiepileptic medications in patients with epilepsy. As part of the review, they examined the data available on innovator versus generic drugs.116 The strength of evidence for the 18 articles that met inclusion criteria was rated primarily as low or insufficient. They did not detect a difference between generics and innovators in terms of seizure occurrence, seizure frequency, blood concentrations, or adverse events. There are continuing discussions between the neurology community and the FDA as to how equivalence should be best determined. It is important to recognize that there is no requirement for bioequivalence testing between generic manufacturers. In lieu of data either supporting or disproving generic-to-generic equivalency, it is best if a patient can be maintained on the same manufacturer, if possible. A generic manufacturer can be specified by the prescriber by indicating “dispense as written, medically necessary.” The laws surrounding if and how a pharmacist can substitute when dispensing medication vary by state. www.turner-white.comEpilepsy Volume 1, Part 6 17 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection BOARD REVIEW QUESTIONS Test your knowledge of this topic. Go to www.turner-white.com and select Epilepsy from the drop-down menu of specialties. References 1. Go CY, Mackay MT, Weiss SK, et al. Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2012;78:1974–80. 2. Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: antiepileptic drug selection for people with HIV/ AIDS. report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012;78:139–45. 3. Harden CL, Meador KJ, Pennell PB, et al. Practice parameter update: management issues for women with epilepsy—focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes : report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society. Neurology 2009;73:133–41. 4. Ramsay E, Faught E, Krumholz A, et al; CAPSS-272 Study Group. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: A randomized double-blind clinical trial. Epilepsia 2010;51:1970–77. 5. Brodie MJ, Chadwick DW, Anhut H, et al; Gabapentin Study Group 945-212. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993–1000. 6. Brodie MJ, Perucca E, Ryvlin P, et al; Levetiracetam Monotherapy Study Group. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007;68:402–8. 7. Nieto-Barrera M, Brozmanova M, Capovilla G, et al; Lamictal vs. Carbamazepine Study Group. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Res 2001;46:145–55. 8. Brodie MJ, Barry SJ, Bamagous GA, et al. Patterns of treatment response in newly diagnosed epilepsy. Neurology 2012;78:1548–54. 9. French JA, Kanner AM, Bautista J, et al. Efficacy and tol- 18 Hospital Physician Board Review Manual 10. 11. 12. 13. 14. 15. 16. 17. 18. 19. 20. 21. 22. 23. erability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004 Apr 27;62:1252–60. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261–73. National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. NICE clinical guideline 137. January 2012. http://www.nice. org.uk/nicemedia/live/13635/57779/57779.pdf. Accessed December 17, 2012. St Louis EK, Gidal BE, Henry TR, et al. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav 2007;11:222–34. Troupin AS. Dose-related adverse effects of anticonvulsants. Drug Saf 1996;14:299–328. Verrotti A, D’Egidio C, Mohn A, et al. Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications. Obes Rev 2011;12:e32–43. Verrotti A, Scaparrotta A, Agostinelli S, et al. Topiramate-induced weight loss: a review. Epilepsy Res 2011;95:189–99. Wellmer J, Wellmer S, Bauer J. The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy. Acta Neurol Scand 2009;119:233–8. Pack AM, Morrell MJ, McMahon DJ, Shane E. Normal vitamin D and low free estradiol levels in women on enzyme-inducing antiepileptic drugs. Epilepsy Behav 2011;21:453–8. Lee RH, Lyles KW, Colón-Emeric C. A review of the effect of anticonvulsant medications on bone mineral density and fracture risk. Am J Geriatr Pharmacother 2010;8:34–46. Mintzer S, Skidmore CT, Rankin SJ, et al. Conversion from enzyme-inducing antiepileptic drugs to topiramate: effects on lipids and C-reactive protein. Epilepsy Res 2012;98:88–93. Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012;53:120–8. Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009;65:448–56. Zaccara G, Franciotta D, Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. 2007;48:1223–44. Franciotta D, Kwan P, Perucca E. Genetic basis for idiosyncratic reactions to antiepileptic drugs. Curr Opin Neurol 2009;22:144–9. www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection 24. Cacoub P, Musette P, Descamps V, et al. The DRESS syndrome: a literature review. Am J Med 2011;124:588–97. 25. Alvestad S, Lydersen S, Brodtkorb E. Cross-reactivity pattern of rash from current aromatic antiepileptic drugs. 2008;80:194–200. 26. Hernández-Díaz S, Smith CR, Shen A, et al; North American AED Pregnancy Registry; North American AED Pregnancy Registry. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692–9. 27. Tomson T, Battino D, Bonizzoni E, et al; EURAP study group. Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry. Lancet Neurol 2011;10:609–17. 28. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996–2002. 29. Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs. N Engl J Med 2009;360:1597– 605. 30. Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Foetal antiepileptic drug exposure and verbal versus non-verbal abilities at three years of age. Brain 2011;134(Pt 2):396–404. 31. Meador KJ, Baker GA, Browning N, et al; NEAD Study Group. Effects of fetal antiepileptic drug exposure: outcomes at age 4.5 years. Neurology 2012;78:1207–14. 32. Harden CL, Pennell PB, Koppel BS, et al; American Academy of Neurology; American Epilepsy Society. Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folic acid, blood levels, and breast-feeding: Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2009;50:1247–55. 33. Walker SP, Permezel M, Berkovic SF. The management of epilepsy in pregnancy. BJOG 2009;116:758–67. 34. Gaffield ME, Culwell KR, Lee CR. The use of hormonal contraception among women taking anticonvulsant therapy. Contraception 2011;83:16–29. 35. U.S. Food and Drug Administration. FDA alert: Information for healthcare professionals: suicidal behavior and ideation and antiepileptic drugs. January 31, 2008; updated: December 16, 2008. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm100192.htm. Accessed December 17, 2012. 36. Mula M, Hesdorffer DC. Suicidal behavior and antiepileptic drugs in epilepsy: analysis of the emerging evidence. Drug Healthc Patient Saf 2011;3:15–20. 37. Foldvary-Schaefer N, Falcone T. Catamenial epilepsy: 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49. 50. 51. pathophysiology, diagnosis, and management. Neurology 2003;61(6 Suppl 2):S2–15. Dreifuss FE, Rosman NP, Cloyd JC, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998;338:1869–75. Lamson MJ, Sitki-Green D, Wannarka GL, et al. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, singlecentre study. Clin Drug Investig 2011;31:585–97. Silbergleit R, Durkalski V, Lowenstein D; NETT Investigators. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591–600. Holsti M, Dudley N, Schunk J, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med 2010;164:747–53. Browne TR. Clonazepam. N Engl J Med 1978;299:812–6. Macphee GJ, Brodie MJ. Carbamazepine substitution in severe partial epilepsy: implication of autoinduction of metabolism. Postgrad Med J 1985;61:779–83. Rapeport WG. Factors influencing the relationship between carbamazepine plasma concentration and its clinical effects in patients with epilepsy. Clin Neuropharmacol 1985;8:141–9. Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update. Clin Pharmacokinet 1996;31:198–214. Smith DB, Mattson RH, Cramer JA, et al. Results of a nationwide Veterans Administration Cooperative Study comparing the efficacy and toxicity of carbamazepine, phenobarbital, phenytoin, and primidone. Epilepsia 1987;28 Suppl 3:S50–8. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992;327:765–71. Rowan AJ, Ramsay RE, Collins JF, et al; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005;64:1868–73. Glauser TA, Cnaan A, Shinnar S, et al; Childhood Absence Epilepsy Study Group. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N Engl J Med 2010;362:790–9. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145–51. Sulzbacher S, Farwell JR, Temkin N, et al. Late cognitive www.turner-white.comEpilepsy Volume 1, Part 6 19 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection 52. 53. 54. 55. 56. 57. 58. 59. 60. 61. 62. 63. 64. 65. 66. 67. effects of early treatment with phenobarbital. Clin Pediatr (Phila) 1999;38:387–94. Richens A. Clinical pharmacokinetics of phenytoin. Clin Pharmacokinet 1979;4:153–69. Hung CC, Lin CJ, Chen CC, et al. Dosage recommendation of phenytoin for patients with epilepsy with different CYP2C9/CYP2C19 polymorphisms. Ther Drug Monit 2004;26:534–40. DeToldeo JC, Ramsay RE. Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs. Drug Saf 2000;22:459–66. Knapp LE, Kugler AR. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy. J Child Neurol 1998;13 Suppl 1:S15–8. Dutta S, Reed RC, Cavanaugh JH. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers. J Clin Pharmacol 2004;44:737–42. Bowdle AT, Patel IH, Levy RH, Wilensky AJ. Valproic acid dosage and plasma protein binding and clearance. Clin Pharmacol Ther 1980;28:486–92. Ng YT, Conry JA, Drummond R; OV-1012 Study Investigators. Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome. Neurology 2011;77:1473–81. Onfi [package insert]. Deerfield (IL): Lundbeck; 2011. http:// www.lundbeck.com/upload/us/files/pdf/Products/Onfi_PI_US_ EN.pdf Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf 1999;21:225–39. Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol 1992;32:386–92. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991;41:1785–9. Theodore WH, Raubertas RF, Porter RJ, et al. Felbamate: a clinical trial for complex partial seizures. Epilepsia 1991;32:392–7. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). The Felbamate Study Group in Lennox-Gastaut Syndrome. N Engl J Med 1993;328:29– 33. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993;34 Suppl 7:S18–24. Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clin Pharmacol Ther 1994;56:154–9. Faught E, Morris G, Jacobson M, et al. Adding lamotrigine to valproate: incidence of rash and other adverse effects. 20 Hospital Physician Board Review Manual 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. Postmarketing Antiepileptic Drug Survey (PADS) Group. Epilepsia 1999;40:1135–40. Lamictal [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2011. Gidal BE, Sheth R, Parnell J, et al. Evaluation of VALPROIC ACID dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res 2003;57:85–93. Biton V, Sackellares JC, Vuong A, et al. Double-blind, placebo-controlled study of lamotrigine in primary generalized tonic-clonic seizures. Neurology 2005;65:1737–43. Steinhoff BJ, Ueberall MA, Siemes H, et al; LAM-SAFE Study Group. The LAM-SAFE Study: lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure 2005;14:597–605. Bodenstein-Sachar H, Gandelman-Marton R, Ben-Zeev B, et al. Outcome of lamotrigine treatment in juvenile myoclonic epilepsy. Acta Neurol Scand 2011;124:22–7. Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents, and adults with primary generalized seizures: open-label, noncomparative, multicenter, longterm follow-up study. Epilepsia 2012;53:111–9. Lo BW, Kyu HH, Jichici D, et al. Meta-analysis of randomized trials on first line and adjunctive levetiracetam. Can J Neurol Sci 2011;38:475–86. Rosenow F, Schade-Brittinger C, Burchardi N, et al; for the LaLiMo Study Group. The LaLiMo Trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalised epilepsy--an open-label, prospective, randomised controlled multicenter study. . J Neurol Neurosurg Psychiatry 2012;83:1093–8. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994;35 Suppl 3:S14–9. Dong X, Leppik IE, White J, Rarick J. Hyponatremia from oxcarbazepine and carbamazepine. Neurology 2005;65:1976–8. Trileptal [package insert]. East Hanover (NJ): Novartis; 2011. Beydoun A, Sachdeo RC, Rosenfeld WE, et al. Oxcarbazepine monotherapy for partial-onset seizures: a multicenter, double-blind, clinical trial. Neurology 2000;54:2245–51. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597–607. Sachdeo R, Beydoun A, Schachter S, et al. Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures. Neurology 2001;57:864–71. Zhou Q, Zheng J, Yu L, Jia X. Pregabalin monotherapy for epilepsy. Cochrane Database Syst Rev 2012 Oct 17;10:CD009429. www.turner-white.com Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection 83. Kwan P, Brodie MJ, Kälviäinen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011;10:881–90. 84. Banzel [package insert]. Woodcliff Lake (NJ): Eisai Inc.; 2011. 85. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia 2008;49:1123–41. 86. Glauser T, Kluger G, Sachdeo R, et al. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950–8. 87. Brodie MJ, Rosenfeld WE, Vazquez B, et al. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial. Epilepsia 2009;50:1899–909. 88. Mangano S, Cusumano L, Fontana A. Non-convulsive status epilepticus associated with tiagabine in a pediatric patient. Brain Dev 2003;25:518–21. 89. Skardoutsou A, Voudris KA, Vagiakou EA. Non-convulsive status epilepticus associated with tiagabine therapy in children. Seizure 2003;12:599–601. 90. Vinton A, Kornberg AJ, Cowley M, et al. Tiagabine-induced generalised non convulsive status epilepticus in patients with lesional focal epilepsy. J Clin Neurosci 2005;12:128–33. 91. U.S Food and Drug Adminstration. Information for Healthcare Professionals: Tiagabine hydrochloride (marketed as Gabitril) - seizures in patients without epilepsy FDA Alert [2/18/2005]. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ ucm126114.htm 92. Loring DW, Williamson DJ, Meador KJ, et al. Topiramate dose effects on cognition: a randomized double-blind study. Neurology 2011;76:131–7. 93. Ben-Menachem E, Sander JW, Stefan H, et al. Topiramate monotherapy in the treatment of newly or recently diagnosed epilepsy. Clin Ther 2008;30:1180–95. 94. Malmgren K, Ben-Menachem E, Frisén L. Vigabatrin visual toxicity: evolution and dose dependence. Epilepsia 2001;42:609–15. 95. Tolman JA, Faulkner MA. Vigabatrin: a comprehensive review of drug properties including clinical updates following recent FDA approval. Expert Opin Pharmacother 2009;10:3077–89. 96. Kochak GM, Page JG, Buchanan RA, et al. Steady-state pharmacokinetics of zonisamide, an antiepileptic agent for treatment of refractory complex partial seizures. J Clin Pharmacol 1998;38:166–71. 97. Leppik IE, Willmore LJ, Homan RW, et al. Efficacy and safety of zonisamide: results of a multicenter study. Epilepsy Res 1993;14:165–73. 98. Faught E, Ayala R, Montouris GG; Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 2001;57:1774–9. 99. Brodie MJ, Duncan R, Vespignani H, et al. Dose-dependent safety and efficacy of zonisamide: a randomized, doubleblind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 2005;46:31–41. 100.Gunthorpe MJ, Large CH, Sankar R. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy. Epilepsia 2012;53:412–24. 101.Brickel N, Gandhi P, VanLandingham K, et al. The urinary safety profile and secondary renal effects of retigabine (ezogabine): a first-in-class antiepileptic drug that targets KCNQ (K(v)7) potassium channels. Epilepsia 2012;53:606–12. 102.French JA, Abou-Khalil BW, Leroy RF; RESTORE 1/Study 301 Investigators.Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology 2011;76:1555–63. 103.Brodie MJ, Lerche H, Gil-Nagel A, et al; RESTORE 2 Study Group. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology 2010;75:1817–24. 104.Beyreuther BK, Freitag J, Heers C, et al. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13:21– 42. 105.Ben-Menachem E, Biton V, Jatuzis D, et al. Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures. Epilepsia 2007;48:1308–17. 106.Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, et al; SP755 Study Group. Adjunctive lacosamide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50:443–53. 107.Chung S, Sperling MR, Biton V; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51:958–67. 108.Sake JK, Hebert D, Isojärvi J, et al. A pooled analysis of lacosamide clinical trial data grouped by mechanism of action of concomitant antiepileptic drugs. CNS Drugs 2010;24:1055–68. 109.Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: a summary of the Tenth Eilat Conference (EILAT X). Epilepsy Res 2010;92:89–124. 110.Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408–15. 111.French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized phase III study 304. Neurology 2012;79:589–96. 112.French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of www.turner-white.comEpilepsy Volume 1, Part 6 21 Antiepilepsy Drugs: Pharmacodynamics and Principles of Drug Selection adjunctive perampanel in patients with refractory partialonset seizures: Results of randomized global phase III study 305. Epilepsia 2012 Aug 20. doi: 10.1111/j.15281167.2012.03638.x. [Epub ahead of print] 113.Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: Interim results from phase III, extension study 307. Epilepsia. 2012 Aug 20. doi: 10.1111/j.1528-1167.2012.03648.x. [Epub ahead of print] 114.Liow K, Barkley GL, Pollard JR; American Academy of Neurology. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007;68:1249–50. 115.Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010;70:605–21. 116.Talati R, Scholle JM, Phung OP, et al. Efficacy and safety of innovator versus generic drugs in patients with epilepsy: a systematic review. Pharmacotherapy 2012;32:314–22. Copyright 2012 by Turner White Communications Inc., Wayne, PA. All rights reserved. 22 Hospital Physician Board Review Manual www.turner-white.com